Parallax Volatility Advisers
RARE icon

Parallax Volatility Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Parallax Volatility Advisers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-69
Closed -$5K – 3732
2018
Q3 		$5K Buy
+69
New +$5.61K ﹤0.01% 2319
2018
Q1 		– Sell
-6,090
Closed -$282K – 3819
2017
Q4 		$282K Buy
+6,090
New +$299K ﹤0.01% 1987

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Parallax Volatility Advisers's RARE Position: Q4 2018 in Review

Parallax Volatility Advisers sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 69 shares — an estimated $5K sold.

Parallax Volatility Advisers first reported a position in RARE in Q4 2017 and held it in 2 quarters. The position peaked at $282K in Q4 2017. 164 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

  • Parallax Volatility Advisers reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 69 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $5K.
  • Parallax Volatility Advisers first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Ultragenyx Pharmaceutical position peaked at $282K in Q4 2017.
  • 164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on Parallax Volatility Advisers's 13F filing for Q4 2018, filed 14 Feb 2019.